Quantitative Systematic Strategies LLC reduced its stake in shares of Shire PLC (NASDAQ:SHPG) by 71.7% during the second quarter, Holdings Channel reports. The firm owned 1,345 shares of the biopharmaceutical company’s stock after selling 3,413 shares during the period. Quantitative Systematic Strategies LLC’s holdings in Shire PLC were worth $243,000 at the end of the most recent quarter.
Several other hedge funds have also bought and sold shares of the stock. Duncker Streett & Co. Inc. acquired a new stake in Shire PLC during the second quarter valued at about $111,000. Quadrant Capital Group LLC raised its stake in Shire PLC by 157.6% in the second quarter. Quadrant Capital Group LLC now owns 608 shares of the biopharmaceutical company’s stock worth $101,000 after buying an additional 372 shares during the period. West Oak Capital LLC purchased a new stake in Shire PLC during the second quarter worth $126,000. NEXT Financial Group Inc purchased a new stake in Shire PLC during the second quarter worth $126,000. Finally, North Star Investment Management Corp. purchased a new stake in Shire PLC during the second quarter worth $147,000. 24.26% of the stock is currently owned by institutional investors.
Shares of Shire PLC (NASDAQ:SHPG) traded down 1.75% on Friday, reaching $187.70. 866,453 shares of the company’s stock traded hands. The stock has a 50-day moving average of $194.68 and a 200 day moving average of $187.77. Shire PLC has a 12-month low of $147.60 and a 12-month high of $231.32. The firm has a market cap of $55.91 billion, a P/E ratio of 39.01 and a beta of 1.16.
Shire PLC (NASDAQ:SHPG) last released its quarterly earnings data on Tuesday, August 2nd. The biopharmaceutical company reported $3.38 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.03 by $0.35. The firm had revenue of $2.43 million for the quarter, compared to analysts’ expectations of $2.28 billion. Shire PLC had a net margin of 13.19% and a return on equity of 17.70%. The company’s revenue for the quarter was up 55.9% compared to the same quarter last year. During the same quarter last year, the business posted $2.63 earnings per share. On average, equities research analysts expect that Shire PLC will post $12.92 earnings per share for the current year.
The firm also recently announced a dividend, which was paid on Friday, October 7th. Investors of record on Friday, September 9th were issued a $0.139 dividend. The ex-dividend date of this dividend was Wednesday, September 7th. Shire PLC’s dividend payout ratio (DPR) is presently 15.63%.
A number of analysts recently weighed in on the stock. Piper Jaffray Cos. set a $201.00 target price on shares of Shire PLC and gave the stock a “hold” rating in a report on Saturday, October 1st. Leerink Swann reaffirmed a “buy” rating on shares of Shire PLC in a report on Saturday, October 1st. Citigroup Inc. reaffirmed a “buy” rating on shares of Shire PLC in a report on Wednesday, August 3rd. RBC Capital Markets reaffirmed an “outperform” rating on shares of Shire PLC in a report on Wednesday, August 3rd. Finally, Zacks Investment Research raised shares of Shire PLC from a “sell” rating to a “hold” rating in a report on Thursday, August 4th. Five investment analysts have rated the stock with a hold rating and twenty-two have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $228.15.
Shire PLC Company Profile
Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines.
Want to see what other hedge funds are holding SHPG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Shire PLC (NASDAQ:SHPG).
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.